Paul J. Hastings Sells 17,378 Shares of Nkarta, Inc. (NASDAQ:NKTX) Stock

Nkarta, Inc. (NASDAQ:NKTXGet Free Report) CEO Paul J. Hastings sold 17,378 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $38,231.60. Following the completion of the transaction, the chief executive officer now owns 319,859 shares of the company’s stock, valued at approximately $703,689.80. The trade was a 5.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Nkarta Stock Performance

Shares of NASDAQ NKTX opened at $2.47 on Monday. The company has a market cap of $174.31 million, a PE ratio of -1.31 and a beta of 0.85. The firm’s 50 day moving average price is $2.52 and its 200-day moving average price is $4.18. Nkarta, Inc. has a 52-week low of $2.08 and a 52-week high of $16.24.

Institutional Trading of Nkarta

Institutional investors have recently added to or reduced their stakes in the business. Erste Asset Management GmbH purchased a new position in shares of Nkarta in the third quarter worth $33,000. GAMMA Investing LLC increased its holdings in Nkarta by 110.9% in the 3rd quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock worth $45,000 after buying an additional 5,243 shares in the last quarter. Forefront Analytics LLC purchased a new position in Nkarta in the 2nd quarter worth about $70,000. Intech Investment Management LLC bought a new position in Nkarta during the 3rd quarter valued at about $74,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Nkarta during the 3rd quarter valued at about $93,000. 80.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on NKTX shares. Needham & Company LLC lowered their price objective on Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 8th. HC Wainwright lowered their price target on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Rodman & Renshaw initiated coverage on shares of Nkarta in a report on Wednesday, October 9th. They issued a “buy” rating and a $14.00 price objective on the stock. RODMAN&RENSHAW upgraded shares of Nkarta to a “strong-buy” rating in a report on Wednesday, October 9th. Finally, Mizuho cut their price target on Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Thursday, November 21st. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $15.00.

Get Our Latest Research Report on NKTX

Nkarta Company Profile

(Get Free Report)

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.

See Also

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.